Biotechnology

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

As RNA therapies boom, a new enzymatic platform promises to solve critical manufacturing bottlenecks, making next-gen drugs more scalable and sustainable.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

A new stem cell therapy promises a one-time cure for hemophilia A, and the FDA is clearing the path. Could lifelong, costly infusions become a memory?

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

A new campaign aims to save a major research hub, igniting a debate over its economic benefits, medical breakthroughs, and the future of animal testing.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

MindBio's new tech detects intoxication from your voice, promising safer workplaces but sparking major debate over surveillance, bias, and data privacy.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.

A first-in-class drug, NTX-2001, is now in human trials for alcohol use disorder, offering a new mechanism of action in a field with few options.

HitGen Inc.'s latest sustainability report signals a deep integration of ESG, leveraging its AI-driven R&D platform for both health and environmental gains.

Henlius and Organon's POHERDY gains EC approval, set to expand access and lower costs for a critical breast cancer therapy across the European Union.

A novel topical gel that boosts cellular energy is now in late-stage trials, offering new hope for healing the chronic wounds of diabetic foot ulcers.

New MD Andreas Goppelt brings a bold M&A and digital transformation agenda to OrphaCare, aiming to reshape rare disease patient care globally.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

YPrime's new AI Calculation Engine lets researchers use plain language to build complex trial logic, aiming to slash setup times and boost data accuracy.